New Drug Trial Offers Fresh Hope for Mesothelioma Patients

A groundbreaking drug trial led by the University of Leicester and Cancer Research UK Southampton is offering new hope to people living with mesothelioma, an aggressive cancer that currently has no cure. The NERO trial tested the PARP inhibitor drug niraparib in patients whose mesothelioma had stopped responding to standard treatments. Results presented on 29 April to the American Association for Cancer Research showed promising outcomes for those affected by this devastating disease.

Although the term mesothelioma was first coined in 1908, the disease is believed to have been diagnosed as early as 1779. Despite decades of research, treatment options remain limited, and life expectancy is often poor. PARP inhibitors work by preventing cancer cells from repairing damaged DNA, ultimately leading to their death. Before this trial, PARP inhibitors had been used successfully to improve survival in patients with certain types of breast and ovarian cancers.

The NERO trial included 88 patients across 11 hospitals in the UK, all of whom had mesothelioma that was no longer responding to treatment. Patients who received niraparib experienced a 27% reduction in the risk of cancer progression or death, and cancer progression was delayed by an average of 1.5 months compared to those receiving standard care. The next stage of research will focus on enhancing treatment options further, including analysing how different drugs impact patients with evidence of MTAP (methylthioadenosine phosphorylase), a protein used as a marker in diagnosing malignant mesothelioma. Researchers hope to provide more targeted and effective treatments based on patients’ specific genetic markers.

This discovery offers renewed hope for mesothelioma patients and their families, giving them the possibility of more time together and an improved quality of life. While these trials represent a significant step forward in the fight against asbestos-related cancers, it remains essential to exercise continued vigilance, as preventing asbestos exposure is still critical. To learn more about your responsibilities regarding asbestos, and how Casa can assist in safeguarding you and your employees, For more information we have a list of on our website or contact us directly.